pembrolizumab,cabozantinib,nivolumab,ipilimumab,cemiplimab
bms,merck,sanofi,regeneron
['nivolumab', 'pembro', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'advanced i', 'nivo', 'imab ']
what an amazing global effort to assess efficacy of ici in penile scc. orr was 11% (only 2 pt had cr), 24% had stable disease with 11% treatment discontinuation due to ae profile. #gu23 
@UroOnc fellow @FCUroOnc @caseurology @JohnsHopkinsSPH grad/👦👦👦🐶mom/Health outcomes/translational 🔬 bladder@AbboshLab 🧪 Immunology @DrexelUniv